Segmentation - Antiplatelet Drugs Market

Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Market Dynamics

Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.

Key features of the study:

This report provides an in-depth analysis of the global antiplatelet drugs market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiplatelet drugs market

Detailed Segmentation:

Global Antiplatelet Drugs Market , By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market , By Mode of Administration:
- Oral
- Intravenous
Global Antiplatelet Drugs Market , By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
Global Antiplatelet Drugs Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- AstraZeneca Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

Global Antiplatelet Drugs Market , By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market , By Mode of Administration:
- Oral
- Intravenous
Global Antiplatelet Drugs Market , By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
Global Antiplatelet Drugs Market, By Region:
- North America
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Drug Class:
    - Irreversible Cyclooxygenase (COX) Inhibitors
    - Adenosine Diphosphate (ADP) Receptor Inhibitors
    - Glycoprotein IIB/IIIA Inhibitors
    - Adenosine Reuptake Inhibitors
    - Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  - By Mode of Administration:
    - Oral
    - Intravenous
  - By Application:
    - Angioplasty
    - Arterial Thrombosis
    - Myocardial Infarction
    - Percutaneous Coronary Interventions
    - Others
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount